Sun Pharmaceutical's shares fell 5.7% to ₹1,608.30 after a 20% drop in net profit to ₹2,278 crore for Q1 FY26. Despite this, revenue grew 9% to ₹13,851 crore, supported by strong performances in key ...

Choice Broking maintained an ‘ADD’ rating and a target price of Rs 1,825 on Sun Pharma. At the prevailing price, the target ...

Sun Pharmaceutical Industries reported a decline of 20 per cent in net profit at Rs. 2,278.63 crore during the first quarter of the current fiscal year, as compared to Rs. 2,835.62 crore during the ...

Sun Pharma stock fell as much as 5.78% during trade so far to Rs 1,608 apiece on the NSE. It was trading 3.65% lower at Rs ...

Healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins ...

Sun Pharmaceutical's shares declined following a reported 20% YoY drop in Q1FY26 net profit, despite a 10% increase in ...

Brokerages have recommended several stocks to buy today (August 1) for long-term gains. The top recommendations are- HUL, IGL, Sun Pharma and Ambuja Cement. Let's take a look at target price below: ...

A host of prominent companies are scheduled to announce their Q1 results today, drawing keen attention from investors and analysts. The lineup includes heavyweights such as Adani Enterprises, Vedanta, ...

Sun Pharma's top management reassures no plans to shift manufacturing to US despite looming tariffs, strong Q1 performance.

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

The recent 25% US tariff on Indian imports threatens over one lakh jobs in India's $9.9 billion gem and jewellery industry.

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...